US 12,269,881 B2
Antigen binding proteins specifically binding MAGE-A
Meike Hutt, Tuebingen (DE); Felix Unverdorben, Tuebingen (DE); Sebastian Bunk, Tuebingen (DE); Dominik Maurer, Tuebingen (DE); Martin Hofmann, Tuebingen (DE); Gabriele Pszolla, Tuebingen (DE); Sara Yousef, Tuebingen (DE); Claudia Wagner, Tuebingen (DE); Frank Schwoebel, Tuebingen (DE); and Heiko Schuster, Tuebingen (DE)
Assigned to Immatics Biotechnologies GmbH, Tübingen (DE)
Filed by Immatics Biotechnologies GmbH, Tuebingen (DE)
Filed on Dec. 13, 2023, as Appl. No. 18/538,242.
Application 18/538,242 is a continuation of application No. 18/483,174, filed on Oct. 9, 2023, abandoned.
Application 18/483,174 is a continuation of application No. 16/943,779, filed on Jul. 30, 2020, granted, now 11,840,577, issued on Dec. 12, 2023.
Claims priority of provisional application 62/905,782, filed on Sep. 25, 2019.
Claims priority of provisional application 62/882,131, filed on Aug. 2, 2019.
Claims priority of application No. 102019121007.0 (DE), filed on Aug. 2, 2019.
Prior Publication US 2024/0117068 A1, Apr. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2809 (2013.01) [A61K 39/461 (2023.05); A61K 39/4632 (2023.05); A61K 39/464486 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/30 (2013.01); C07K 16/468 (2013.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 8 Claims
 
1. A protein that binds both (a) a complex of MAGE-A and human major histocompatibility complex (MHC) protein and (b) a TCRαß, wherein said protein comprises
(a) a first polypeptide comprising
an amino acid sequence that is at least 98% identical to SEQ ID NO: 136 comprising (1) a beta variable (Vβ) domain comprising
(i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 62,
(ii) a CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and
(iii) a CDR3 comprising the amino acid sequence of SEQ ID NO: 71; and
(2) an antibody light chain variable (VL) domain comprising the amino acid sequence of SEQ ID NO: 159; and
(b) a second polypeptide comprising
an amino acid sequence that is at least 98% identical to SEQ ID NO: 137 comprising (1) an alpha variable (Vα) domain comprising
(i) a CDR1 comprising the amino acid sequence of SEQ ID NO: 5,
(ii) a CDR2 comprising the amino acid sequence of SEQ ID NO: 56, and
(iii) a CDR3 comprising the amino acid sequence of SEQ ID NO: 35, and
(2) an antibody heavy chain variable (VH) domain comprising the amino acid sequence of SEQ ID NO: 160; and wherein
the Vα and the Vβ form a binding site that binds to the MAGE-A/MHC complex and the VL and VH form a binding site that binds to the TCRαß.